HE 2200
Alternative Names: androstenetriol; ReversionexLatest Information Update: 29 Nov 2007
At a glance
- Originator Virginia Commonwealth University
- Developer Hollis-Eden Pharmaceuticals
- Class Antihyperlipidaemics; Hormones
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Hypercholesterolaemia; Immunodeficiency disorders; Inflammatory bowel diseases; Multiple sclerosis; Neutropenia; Shock
Most Recent Events
- 18 Aug 2003 Hollis-Eden has completed enrolment in a phase II trial for hypercholesterolaemia
- 22 Apr 2003 Phase-II clinical trials in Immunodeficiency disorders in USA (SC)
- 11 Mar 2003 HE 2200 is available for licensing (http://www.holliseden.com)